X
[{"orgOrder":0,"company":"Horizon Discovery Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Discovery and Pharmahungary Report Positive Early-Stage Results for Novel Micro-RNA Therapeutic","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Horizon Discovery Group","sponsor":"TrueBinding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Horizon Discovery Licenses CHOSOURCE Platform to Truebinding for Development and Commercialization of Multiple Biotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]
Find Clinical Drug Pipeline Developments & Deals by Horizon Discovery Group
Filters
Companies By Therapeutic Area
Details:
TrueBinding will use Horizon’s cGMP-compliant CHOSOURCE™ platform for the development and commercialization of multiple biotherapeutic products for applications in immuno-oncology and other disease areas with great unmet medical need.
Lead Product(s):
Chinese Hamster Ovary K1 cell
Therapeutic Area: Oncology
Product Name: Chosource
Highest Development Status: Discovery Platform
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
TrueBinding
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
July 29, 2020
Details:
The micro-RNA was identified as suitable for further development based on favorable pharmacokinetic results as well as pharmacodynamic data at the molecular level.
Lead Product(s):
miRNA-125b
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 31, 2020